drugset / Trial / NCT01288677

TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers

NCT01288677 ↗

Phase 1 Completed 54 enrolled Tibotec Pharmaceuticals, Ireland
RandomizedSingle-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of single oral doses of TMC649128 in healthy volunteers. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.

Timeline

Start
2011-01
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TMC649128 Small molecule — Oral

Indications

No indication recorded.